| 2010-02-01: |
First Treatment to Improve Survival in 20 Years
Osaka, Japan and London ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( "Takeda" ) and Takeda Pharmaceuticals Europe Limited ( "TPEU" ), its wholly owned subsidiary for oversight of pan - European sales and marketing, jointly announced today that Mepact( R ) ( mifamurtide )( 1 ), the first new treatment in 20 years to improve survival (...) |
| 2010-02-01: |
Cephalon, Inc. Announces Agreement to Acquire Mepha AG
FRAZER, Philadelphia, AESCH, Switzerland and MAISONS ALFORT, France, February 1 ( PRN/ots ) - - Cephalon, Inc. announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately - held, Swiss - based pharmaceutical company. Mepha has specific expertise in innovative dosage (...) |
| 2010-01-25: |
AMP Supports the Creation of a National Immunization Technical Advisory Group in Côte d'Ivoire
Paris ( PRN/ots ) - On January 15, the Minister of Health and Hygiene of Côte d'Ivoire, Dr. Rémi Allah Kouadio, presided over a ceremony to mark the launch of a National Immunization Technical Advisory Group ( NITAG ) named "Côte d'Ivoire National Committee of Independent Experts for (...) |
| 2010-01-21: |
Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
Abbott Park, Illinois ( PRN/ots ) - Today the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) voted to recommend the suspension of marketing authorizations for all anti - obesity medicines containing sibutramine. Abbott will comply with the CHMP recommendation and (...) |
| 2010-01-21: |
New Real World Avastin Data From Over 3,200 Metastatic Colorectal Cancer Patients Confirms Survival Benefit Beyond 2 Years
Basel, Switzerland ( PRN/ots ) - New data from two large studies observing the routine use of Avastin - based therapy in more than 3,200 patients will be announced showing impressive treatment benefits in a non - selected patient population. Key findings included high rates of tumour shrinkage (...) |
| 2010-01-14: |
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Park, Illinois ( PRN/ots ) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment (...) |
| 2010-01-07: |
Tolerx Completes Enrollment in DEFEND - 1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND - 1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new - onset autoimmune type 1 diabetes. (...) |
| 2010-01-06: |
New Abbott Gene - Based Test for Colorectal Cancer Receives CE Mark
Des Plaines, Illinois ( PRN/ots ) - Abbott announced today it has received CE Marking ( Conformite Europeene ) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non - invasive DNA assay that detects the methylated form of Septin 9, a (...) |
| 2010-01-05: |
New Analysis Showed Efient( R ) Cost - Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Tokyo and Indianapolis ( PRN/ots ) - Results from a health economic substudy of the TRITON - TIMI 38 clinical trial showed that among patients with acute coronary syndrome ( ACS ) managed with percutaneous coronary intervention ( PCI ), including stenting, treatment with Efient( R ) ( prasugrel ) compared with branded clopidogrel ( Plavix( R ) ) was (...) |
| 2010-01-04: |
Pieris Appoints a New CEO / Appointment will bring substantial deal - making expertise to the company
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co - founder Claus Schalper, who will remain CFO. Mr. Yoder joins (...) |
| 2009-12-22: |
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX - 208, Resverlogix's oral small molecule therapy for the treatment of (...) |
| 2009-12-21: |
Medicago Reports Positive Phase I Results for its Avian Flu Pandemic Vaccine
Quebec City ( PRN/ots ) - Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus - Like Particles ( VLPs ), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine (...) |
| 2009-12-18: |
Amgen Receives CHMP Positive Opinion for Prolia( TM ) ( Denosumab ) in the European Union
Thousand Oaks, California ( PRN/ots ) - Amgen Inc. today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has announced a positive opinion for the marketing authorization of Prolia( TM ) ( denosumab ) for the treatment of osteoporosis in postmenopausal (...) |
| 2009-12-17: |
FDA Broadens Clearance for Agendia's MammaPrint( R )
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration ( FDA ) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA - cleared breast cancer (...) |
| 2009-12-17: |
Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany ( PRN/ots ) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late - stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME - Ovar - 1 (...) |
| 2009-12-05: |
Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha
Cape Town, South Africa ( PRN/ots ) - The first Football for Hope Centre in Khayelitsha in the outskirts of Cape Town opened its doors today ( 5 December 2009 ). FIFA President Joseph S. Blatter was joined by Western Cape Premier Helen Zille, 2010 FIFA World Cup (...) |
| 2009-12-04: |
Supporting innovative pain research / EFIC - Grunenthal Grant 2009 awarded to five young scientists
Aachen ( na Originaltextservice ) - The European Federation of Chapters of the International Association for the Study of pain ( EFIC ) and the pharmaceutical company Grunenthal awarded the EFIC - Grunenthal Grant to five young European scientists. The grant will provide financial support for their (...) |
| 2009-12-01: |
Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint( R )
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA - cleared breast cancer recurrence test, which (...) |
| 2009-12-01: |
Men, Partners and Patients in Europe United Against Prostate Cancer
Barcelona, Spain ( PRN/ots ) - - New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting (...) |
| 2009-11-30: |
Sanofi - aventis: Multaq( R ) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 ( PRN/ots ) - - First New Anti - Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the European Commission has granted marketing authorization for Multaq( R ) ( dronedarone - (...) |
| 2009-11-18: |
Boehringer Ingelheim and GlaxoSmithKline Back EFA's Call for Urgent Improvements in Care for People With Lung Disease This World COPD Day
Brussels, Ingelheim, Germany and London, November 18 ( PRN/ots ) - Boehringer Ingelheim and GSK, companies with a strong heritage in COPD ( chronic obstructive pulmonary disease ) and a commitment to improved patient care, have today announced their support of The European Federation of Allergy and (...) |
| 2009-11-17: |
Video: Crestor( R ) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study
Orlando, Florida, November 17 ( PRN/ots ) - JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular ( CV ) events in women without established cardiovascular disease ( CVD ). In this new analysis of 6,801 women (...) |
| 2009-11-17: |
FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
Lake Zurich, Illinois, November 17 ( PRN/ots ) - - Experts to Re - examine Guidance for Platelet Testing Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has cleared (...) |
| 2009-11-16: |
Abbott Announces Positive Three - Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large - Scale International Trial
Orlando, Florida, November 16 ( PRN/ots ) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott ( NYSE: ABT ) today announced three - year data from the first 30 patients in the first phase of the ABSORB (...) |
| 2009-11-16: |
Sanofi - aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 ( PRN/ots ) - - The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today the launch of the RealiseAF registry (...) |
| 2009-11-16: |
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre - Menopausal Women With Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany, November 16 ( PRN/ots ) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under - Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg (...) |
| 2009-11-12: |
Women with HIV: A Growing Challenge
Cologne, Germany, November 12 ( PRN/ots ) - - With Women Comprising Over Half of the Global HIV/AIDS Population,( 1 ) Leading Experts to Convene to Explore the Impact of Gender on Treatment and Care With 33 million individuals infected, HIV/AIDS has long been classified (...) |
| 2009-11-06: |
Ortho Clinical Diagnostics Launches First - of - its - kind Remote Monitoring Center in Europe
Paris, November 6 ( PRN/ots ) - - 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS( R ) Systems PARIS, November 6 /PRNewswire/ - - Ortho Clinical Diagnostics ( OCD ) today announced the (...) |
| 2009-11-04: |
Ortho Clinical Diagnostics Launches First - of - its - kind Remote Monitoring Center in Europe
Paris, November 4 ( PRN/ots ) - - 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS( R ) Systems Ortho Clinical Diagnostics ( OCD ) today announced the launch of a first - of - (...) |
| 2009-10-30: |
Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival
London ( PRN/ots ) - - Eisai Plans to Submit Marketing Authorization Applications for. Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer Eisai Co., Ltd. ( Headquarters: Tokyo, President and CEO: Haruo Naito ) today announced preliminary results from a recently completed Phase III study with (...) |
| 2009-10-26: |
Three European Analyses Showed Efient is Cost - Effective Compared with Clopidogrel in Patients with Acute Coronary Syndrome Undergoing PCI
Paris ( PRN/ots ) - Results from three separate European health economic analyses of the TRITON - TIMI 38 study showed that treatment with Efient( R ) ( prasugrel ) compared with clopidogrel ( Plavix( R ) ) reduced medical costs by lowering rehospitalisation rates and the need for repeat percutaneous coronary interventions ( PCI ), (...) |
| 2009-10-20: |
Excellence in Epilepsy Journalism Award
Brussels ( PRN/ots ) - - IBE and UCB Announce Winners of Award to Improve Understanding of Epilepsy Around the World The International Bureau of Epilepsy and UCB are pleased to announce the winners of the Excellence in Epilepsy Journalism Award 2009. To view the (...) |
| 2009-10-20: |
'Improvement through Movement' educational programme launched for people with osteoporosis / Pan - European osteoporosis patients encouraged to dance their way to stronger bones
Munich, Germany ( na Originaltextservice ) - An educational programme available on DVD is launched today, on World Osteoporosis Day, bringing together the glamorous world of ballroom dance with the serious nature of disease management. Sponsored by DAIICHI SANKYO EUROPE and endorsed by the (...) |
| 2009-10-09: |
Pieris reports preclinical development progress of its next generation VEGF antagonist / PRS - 050 program on track to commence clinical trials as planned
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic. Under its manufacturing agreement with Wacker (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
